Medical Marijuana Update: Patients are Opting for CBD Instead of Rx Medication

Medical Marijuana Update: Patients are Opting for CBD Instead of Rx Medication

Medical Marijuana Update: Patients are Opting for CBD Instead of Rx Medication

$POTN

A recent study reveals at 40% of patients who consume high-CBD forms of cannabis stopped using traditional pharmaceutical medications and now use marijuana to treat their symptoms.

The survey was conducted by Brightfield Group, a market research firm focused on the legal Cannabis industry, in partnership with HelloMD, an online healthcare platform for Cannabis.

This is the largest know study to date specifically researching CBD usage and its effectiveness for treating a variety of medical conditions including insomnia, depression, anxiety, and joint pain.

CBD, or cannabidiol, is one of the primary cannabinoids found in Cannabis.

Unlike THC, the primary psychoactive cannabinoid in Marijuana, CBD is non-psychoactive and is known to have anti-inflammatory, anti-anxiety, anti-psychotic, and anti-convulsant properties.

“We are seeing an exponential rise in the interest of CBD products from our patient community—particularly among women,” said the Chief Medical Officer of HelloMD. “While we still have much to learn about CBD, we cannot ignore this one fact; the majority of those using CBD product today receive great benefit. This has the potential for far-reaching consequences.”

Key findings from the study include the following;

  1. 42% of CBD users stopped using traditional medications and now use Cannabis instead
  2. 80% of CBD users found CBD be very or extremely effective for treatment.
  3. 90% of those surveyed said they would buy CBD-only products derived from Marijuana.

“This study is exciting because it shows there is potentially a huge barely-tapped market for CBD products that could improve the lives of many people. With further research and public education, CBD could be an effective alternative treatment for many people, particularly at a time when our nation is in the midst of an opioid crisis,” said the Director of Research for Brightfield Group.

POTNETWORK HLDGS I (OTCMKTS:POTN) Lets Do Some Math

So how many shares did OTCMKTS:POTN Print last quarter?

The Company announced the retirement of 300,000,000 common shares held by principal shareholders, but that wast not actually true they will be exchanged for non-trading preferred shares, so untill you know how “preferred” they are then it may be good or bad but 300m shares are NOT being retired, nothing can be said about this as there is not enough information.

What if each preferred is worth 1m shares? what if it entitles the holder to a parentage of the profits, whats left for shareholders? No one can tell you this is good or bad because there are not enough details.

Upon retirement, this reduction will bring the Company’s current issued and outstanding common shares of 569,920,485 down to a total of 269,920,485 issued and outstanding common shares, 569m really they printed 100m shares already last quarter?.

How Shareholders can cash in on POTN.

I do like to make money and see other people make money, so here is my advice if you are long POTN.

Write to or call


Worldwide Stock Transfer, LLC

Transfer Agent
1 University Plaza
Suite 505
Hackensack, NJ 07601
201-820-2008
www.wwstr.com

Ask them how those .003 conversions can be legal, not making acquisitions, just for informational purposes. Ask what lawyer is writing the opinions.

Securities Counselors, Inc
1333 Sprucewood Lane
Deerfield, MA, 60015
United States

Ask them the same questions.

Ask the lawyers who Sign is the holder of the note so you can research it.

If enough of you do that you shut down that questionable conversion practice and the stock could hit 12c.

If you do nothing 10s of millions of shares will go to Sign every quarter, the preferred shares might suck up the profit or you stake in POTN and you will be left, another victim of the anonymous message boards pumpers.

The following two tabs change content below.

Paul Ebeling

Paul A. Ebeling, polymath, excels in diverse fields of knowledge. Pattern Recognition Analyst in Equities, Commodities and Foreign Exchange and author of “The Red Roadmaster’s Technical Report” on the US Major Market Indices™, a highly regarded, weekly financial market letter, he is also a philosopher, issuing insights on a wide range of subjects to a following of over 250,000 cohorts. An international audience of opinion makers, business leaders, and global organizations recognizes Ebeling as an expert.

You must be logged in to post comments :  
CONNECT WITH